S. Minton

619 total citations
13 papers, 243 citations indexed

About

S. Minton is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Minton has authored 13 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Minton's work include Cancer Treatment and Pharmacology (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). S. Minton is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). S. Minton collaborates with scholars based in United States. S. Minton's co-authors include Pamela N. Münster, Douglas C. Marchion, Adil Daud, Alberto Chiappori, Merrill J. Egorin, George R. Simon, Ji‐Hyun Lee, Gregory M. Springett, Scott Thomas and Dan M. Sullivan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Critical Care Medicine.

In The Last Decade

S. Minton

12 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Minton United States 7 157 65 31 31 21 13 243
A. Broxson United States 5 99 0.6× 92 1.4× 80 2.6× 15 0.5× 7 0.3× 6 257
Mary Beth Nierengarten United States 7 53 0.3× 59 0.9× 26 0.8× 13 0.4× 9 0.4× 80 202
Patrícia Taranto Brazil 9 113 0.7× 81 1.2× 17 0.5× 43 1.4× 6 0.3× 17 306
Caela Miller United States 9 86 0.5× 51 0.8× 12 0.4× 35 1.1× 23 1.1× 20 303
Ibrahim Altedlawi Albalawi Saudi Arabia 8 93 0.6× 43 0.7× 26 0.8× 10 0.3× 9 0.4× 33 230
Marta Perachino Italy 7 33 0.2× 139 2.1× 71 2.3× 61 2.0× 11 0.5× 18 250
Sarah M. Lima United States 5 36 0.2× 131 2.0× 20 0.6× 21 0.7× 9 0.4× 14 238
Mahasti Saghatchian France 7 101 0.6× 82 1.3× 42 1.4× 20 0.6× 17 0.8× 15 317
Myria Galazi United Kingdom 7 49 0.3× 63 1.0× 57 1.8× 33 1.1× 9 0.4× 19 190
Polly A. Newcomb United States 5 42 0.3× 100 1.5× 14 0.5× 34 1.1× 9 0.4× 5 196

Countries citing papers authored by S. Minton

Since Specialization
Citations

This map shows the geographic impact of S. Minton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Minton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Minton more than expected).

Fields of papers citing papers by S. Minton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Minton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Minton. The network helps show where S. Minton may publish in the future.

Co-authorship network of co-authors of S. Minton

This figure shows the co-authorship network connecting the top 25 collaborators of S. Minton. A scholar is included among the top collaborators of S. Minton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Minton. S. Minton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Molife, L. Rhoda, S. Minton, Dan M. Sullivan, et al.. (2011). 1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours. European Journal of Cancer. 47. S144–S145. 1 indexed citations
3.
Münster, Pamela N., Douglas C. Marchion, Scott Thomas, et al.. (2009). Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. British Journal of Cancer. 101(7). 1044–1050. 135 indexed citations
4.
5.
Münster, Pamela N., M. Lacevic, Mark R. Schmitt, et al.. (2008). Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. Journal of Clinical Oncology. 26(15_suppl). 3501–3501. 14 indexed citations
6.
Ismail‐Khan, Roohi, S. Minton, Catrin Cox, et al.. (2008). Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 524–524. 28 indexed citations
7.
Münster, Pamela N., Douglas C. Marchion, Morgen Schmitt, et al.. (2007). Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1065–1065. 4 indexed citations
8.
Daud, Adil, Morgen Schmitt, Douglas C. Marchion, et al.. (2007). Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies. Journal of Clinical Oncology. 25(18_suppl). 3502–3502. 8 indexed citations
9.
Moulder, Stacy L., Nikola Valkov, S. Minton, et al.. (2006). A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors?. Journal of Clinical Oncology. 24(18_suppl). 661–661. 2 indexed citations
10.
Moulder, Stacy L., Pamela N. Münster, S. Minton, et al.. (2005). Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 679–679. 1 indexed citations
11.
Münster, Pamela N., Carolyn D. Britten, S. Minton, et al.. (2004). Phase I and pharmacokinetic (PK) Study of CP-724,714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor. Journal of Clinical Oncology. 22(14_suppl). 3082–3082. 1 indexed citations
12.
Minton, S., et al.. (1997). Nurse/physician collaborative practice: improving health care quality while decreasing cost.. PubMed. 15(2). 87–91, 104. 26 indexed citations
13.
Banner, William, Donald D. Vernon, S. Minton, & J. Michael Dean. (1991). Nonlinear dobutamine pharmacokinetics in a pediatric population. Critical Care Medicine. 19(7). 871–873. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Broxson Breakdown of academic impact, for papers by Mary Beth Nierengarten Breakdown of academic impact, for papers by Patrícia Taranto Breakdown of academic impact, for papers by Caela Miller Breakdown of academic impact, for papers by Ibrahim Altedlawi Albalawi Breakdown of academic impact, for papers by Marta Perachino Breakdown of academic impact, for papers by Sarah M. Lima Breakdown of academic impact, for papers by Mahasti Saghatchian Breakdown of academic impact, for papers by Myria Galazi Breakdown of academic impact, for papers by Polly A. Newcomb
Rankless by CCL
2026